title: Expression of the lung resistance protein (LRP) in primary breast cancer.
abstract: BACKGROUND
  To determine the clinical significance of the lung resistance protein (LRP) in breast cancer, we have studied its expression in primary breast carcinomas (n = 99) and assessed the association of this expression with clinical parameters of the patients.
  
  
  METHODS
  LRP expression was immunohistochemically determined by means of the monoclonal antibody LRP-56 on frozen tumor sections.
  
  
  RESULTS
  LRP expression was negative in 12%, low in 20%, intermediate in 47% and high in 21% of the carcinomas. LRP expression was independent of age of the patients, histology, tumor grade, estrogen receptor as well as progesterone receptor status, tumor size and lymph node involvement. Kaplan-Meier analyses revealed that both overall survival and disease-free survival were independent of the degree of LRP expression.
  
  
  CONCLUSIONS
  LRP is frequently expressed in breast carcinomas, but is neither associated with known prognostic factors, nor a prognostic factor by itself.
authors.affiliation: Department of Internal Medicine I, University of Vienna, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Pohl
authors.forename: M
authors.initials: M
authors.lastname: Filipits
authors.forename: R W
authors.initials: RW
authors.lastname: Suchomel
authors.forename: T
authors.initials: T
authors.lastname: Stranzl
authors.forename: D
authors.initials: D
authors.lastname: Depisch
authors.forename: R
authors.initials: R
authors.lastname: Pirker
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000378:metabolism*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000378:metabolism*; D011379:Prognosis; D015996:Survival Rate; D020394:Vault Ribonucleoprotein Particles / Q000378:metabolism*; D000099187:Major Vault Protein
chemical_list: D009363:Neoplasm Proteins; D020394:Vault Ribonucleoprotein Particles; D000099187:Major Vault Protein